Pharmacokinetics of Antituberculosis Drugs in Plasma and Cerebrospinal Fluid in a Patient with Pre-Extensive Drug Resistant Tuberculosis Meningitis.
Zhilin LiangWeiming LiaoQifu ChenHui LiMeiling YeJin ZouGuofang DengPeize ZhangPublished in: Infection and drug resistance (2023)
Drug-resistant tuberculous meningitis (TBM) is the most devastating and critical form of extrapulmonary tuberculosis. Here, we present a case of a 45-year-old male with pre-extensive drug-resistant tuberculosis meningitis (pre-XDR-TBM). He underwent emergency surgery for the long-tunneled external ventricular drainage (LTEVD). Molecular test and phenotypic drug sensitivity test (DST) of Mycobacterium tuberculosis in cerebrospinal fluid (CSF) showed that the isolate was resistant to both rifampin and fluoroquinolones. An anti-tuberculous regimen of isoniazid, pyrazinamide, cycloserine, moxifloxacin, clofazimine, and linezolid was tailored accordingly. We monitored the drug concentration in his plasma and CSF before (at 0-hour) and after anti-TB drugs administration (at 1-hour, 2-hour, 6-hour, and 12-hour) on 10 th day after treatment initiation. We hope to provide reference values of drug exposures in plasma and CSF for patients with pre-XDR-TBM.
Keyphrases
- drug resistant
- mycobacterium tuberculosis
- cerebrospinal fluid
- multidrug resistant
- blood pressure
- acinetobacter baumannii
- pulmonary tuberculosis
- adverse drug
- healthcare
- public health
- heart failure
- drug induced
- hepatitis c virus
- left ventricular
- pseudomonas aeruginosa
- ultrasound guided
- coronary artery disease
- methicillin resistant staphylococcus aureus
- coronary artery bypass
- percutaneous coronary intervention
- atrial fibrillation
- single molecule
- hiv infected
- antiretroviral therapy